Profile data is unavailable for this security.
About the company
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
- Revenue in USD (TTM)0.00
- Net income in USD-212.17m
- Incorporated2014
- Employees164.00
- LocationCogent Biosciences Inc275 Wyman Street, 3Rd FloorWALTHAM 02451United StatesUSA
- Phone+1 (617) 945-5576
- Websitehttps://www.cogentbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exscientia PLC (ADR) | 25.50m | -185.36m | 655.82m | 483.00 | -- | 1.45 | -- | 25.72 | -1.47 | -1.47 | 0.2029 | 3.59 | 0.0346 | 1,096.08 | 9.86 | 52,791.80 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 664.84m | 100.00 | -- | 1.84 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 669.20m | 610.00 | -- | 1.66 | -- | 2.67 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 673.22m | 40.00 | -- | 2.12 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 684.88m | 117.00 | -- | 14.33 | -- | 29.83 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 698.53m | 224.00 | -- | 1.16 | -- | 10,272.55 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 704.13m | 487.00 | -- | 0.9976 | -- | 7.73 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 711.36m | 164.00 | -- | 3.55 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 724.47m | 110.00 | -- | 4.61 | -- | 92.35 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| National Research Corporation | 147.42m | 30.36m | 740.20m | 435.00 | 25.01 | 20.04 | 20.38 | 5.02 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 740.34m | 74.00 | -- | 4.35 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 745.27m | 1.92k | 56.64 | 2.76 | 15.30 | 0.7456 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 752.21m | 53.00 | -- | 2.02 | -- | 233.31 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Humacyte Inc | 0.00 | -105.70m | 753.80m | 183.00 | -- | 28.82 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 765.71m | 266.00 | -- | 30.16 | -- | 6.78 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
Data as of May 20 2024. Currency figures normalised to Cogent Biosciences Inc's reporting currency: US Dollar USD
61.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 31 Mar 2024 | 8.50m | 8.89% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.63m | 7.98% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 6.96m | 7.28% |
| Point72 Asset Management LPas of 31 Mar 2024 | 6.68m | 6.98% |
| Commodore Capital LPas of 31 Mar 2024 | 6.43m | 6.72% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.07m | 6.35% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.61m | 5.87% |
| Fairmount Funds Management LLCas of 31 Mar 2024 | 4.73m | 4.94% |
| Redmile Group LLCas of 31 Mar 2024 | 3.96m | 4.14% |
| Millennium Management LLCas of 31 Mar 2024 | 2.36m | 2.46% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
